Swiss SMI index rises as Roche stock leads daily market gains

The Swiss SMI benchmark index gained 77 points, or 0.5 percent, to close at 14,539 points on October 26, 2026. According to ad-hoc-news.de, citing RTTNews, the index finished slightly below its session high of 14,544 points following a brief early dip. Easing inflation concerns and investor optimism over upcoming corporate financial results supported the advance. [1]

Roche was the primary contributor to the rise, gaining 1.4 percent. Ad-hoc-news.de, citing Moneycab, reported that the increase followed positive trial data from a lung-cancer study and a price-target increase by analysts at JPMorgan. Conversely, shares of Novartis fell 0.4 percent ahead of the company releasing its third-quarter financial report. [1]

Roche maintains a strong focus on oncology therapies. Oncology accounts for roughly 34 percent of the revenue generated by the pharmaceutical division of Roche, which includes treatments such as Avastin and Tecentriq. [3]

Global equity markets have seen positive momentum recently driven by earnings. As FTMQ Business reported earlier, strong corporate earnings and artificial intelligence investments previously lifted United States stock indexes, including a $4.4 billion quarterly profit reported by SpaceX. [4]